Form 8-K - Current report:
SEC Accession No. 0001193125-25-037586
Filing Date
2025-02-27
Accepted
2025-02-27 07:11:52
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d865236d8k.htm   iXBRL 8-K 26112
2 EX-99.1 d865236dex991.htm EX-99.1 88198
6 GRAPHIC g865236g0226210416653.jpg GRAPHIC 2721
  Complete submission text file 0001193125-25-037586.txt   257448

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250227.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250227_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250227_pre.xml EX-101.PRE 11265
18 EXTRACTED XBRL INSTANCE DOCUMENT d865236d8k_htm.xml XML 3706
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 25672975
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)